[Baltimore Session] Meet with...Johnson & Johnson Innovation
[Baltimore Session] Meet with...Johnson & Johnson Innovation
1812 Ashland Avenue , Suite 110, Conf. Room H/J , East Baltimore , MD 21205
November 02, 2017 from 11:30 AM to 14:00 PM (EST)
$10 - $35
How can Johnson & Johnson Innovation (JJI) help you reach your goals? We know what you, the innovator, need to get your science to patients. It is because of you that JJI created regional centers that host a diverse team of science and transaction experts whose goal is to find high potential early-stage innovation and, if on strategy and a fit for Johnson & Johnson, create customized deal structures to help accelerate the science to the patient.
We are also supporting innovation in major life science clusters through the life science incubator, Johnson & Johnson Innovation, JLABS, with the ultimate aim of enabling commercialization of new healthcare solutions for patients. At Johnson & Johnson Innovation, we recognize that a good idea can come from anywhere, and we work with partners at all stages of research and development to nurture the innovation ecosystem and propel the best ideas into solutions for patients.
On November 2, we are coming to Baltimore. Hear from Johnson & Johnson Innovation leaders as they provide an overview of J&J Innovation goals and mission, highlighting how J&J Innovation interacts with the entrepreneurial community through JLABS, JJDC, and other J&J Innovation initiatives.
Speakers will also be on hand to meet with a handful of applicants one-on-one after the presentation.
Areas of interest include:
- Baby care
- Compromised skin
- Feminine personal care
- Oral care
- Vision care
- Infectious Diseases & Vaccines
- Cardiovascular & Metabolism
10:30 AM | Registration Opens and Networking
11:00 AM | Presentation and Q&A
12:30 PM | Networking Lunch
1:00-5:00 PM | One-on-one Meetings*
*Entrepreneurs must have applied for a one-on-one meeting ahead of time and be approved. The application period ends on October 12.
1812 Ashland Avenue,
Suite 110, Conf. Room H/J
Baltimore, MD 21205
Ibraheem Badejo | Senior Director, New Ventures, Johnson & Johnson Innovation read bio»
Dana Deardorff | Senior Director, New Ventures, Johnson & Johnson Innovation read bio»
Stefanie Dhanda | Senior Director, Consumer Scientific Innovation, Johnson & Johnson Innovation read bio»
Nicola La Monica | Senior Director, Infectious Disease and Vaccines Scientific Innovation, Janssen R&D read bio»
Kuldeep Neote | Senior Director, New Ventures, Johnson & Johnson Innovationread bio»
Eric Schaeffer | Senior Director, Neuroscience Scientific Innovation, Janssen R&D read bio»
Presentation & Lunch
FREE | General Public
FREE | Onsite
Includes presentation, Q&A, and lunch. All attendees must register, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until noon on November 1st (or sold out).
FREE | Application
FREE | Accepted Companies
Entrepreneurs must apply for a one-on-one meeting ahead of time. The one-on-one application period ends on October 12th. Established companies as well as researchers, faculty, and entrepreneurs are welcome to apply for these meetings. Your application will be reviewed and you will be notified of acceptance by email. Acceptance of one-on-one meetings is not guaranteed as all applications must be approved.
Participating Representatives' Biographies:
Ibraheem Badejo, Ph.D. | Senior Director, New Ventures, Johnson & Johnson Innovation, Boston
Ibraheem (Ib) is Senior Director, New Ventures at Johnson & Johnson Innovation, Boston. He leverages his expertise in smart materials and biomaterials to support the medical device sector. From 2010 to 2013, Ib was a Research Fellow at Global Surgery Group of Johnson & Johnson, where he was responsible for external and front-end innovations and intellectual property for Ethicon Biosurgery. From 2006 to 2010, he was the Director of Applied Research & New Technology Assessment of novel biomaterials. Prior to that, he was the Chief Scientist of Closure Medical Corp (acquired by J&J in 2005). Prior to joining Closure, he held various positions at Bayer, North Carolina State University, College of Charleston. He currently serves as an Adjunct Professor of Biomedical Engineering at Drexel University. During his career, Ib has led teams in the development of commercialized biomaterials based products and new technology / products licensed or acquired. Ib received his BA degree in chemistry from Avila University. He received his PhD in Organic chemistry from the University of Toledo, where he was the Robert Whiteford Memorial Scholar for Outstanding Graduate Research and a Petroleum Research Fund Fellow. He is also the recipient of 24 US patents with others pending.
Connect with Ibraheem:
Dana Deardorff, Ph.D. | Senior Director, New Ventures, Johnson & Johnson Innovation
Dana Deardorff, Ph.D. recently joined Johnson & Johnson Innovation as the Senior Director of New Ventures for medical devices. In this role, Dana is responsible for developing and investing in early-stage technologies of strategic interest across the medical device sector within J&J. Dana has over 20 years of experience in the medtech industry in various roles bridging technology and business. Previously he worked for Covidien in several leadership positions including VP of Advanced Technology, Strategy & Portfolio Management, and Business Development. Dana has also been an entrepreneur, starting multiple companies as a co-founder and leading technology and product development activities. Most recently he served as an Entrepreneur-in-Residence and advisor to the University of Illinois, helping to evaluate and accelerate the commercial potential of innovative technologies. Dana has a joint doctorate in biomedical engineering from UC-Berkeley and UC-San Francisco and a bachelor's degree in physics from Illinois Wesleyan University.
Connect with Dana:
Stefanie Dhanda | Senior Director, Consumer Scientific Innovation, Johnson & Johnson Innovation
Stefanie is Senior Director of Consumer Scientific Innovation at Johnson & Johnson Innovation, Boston. Stefanie leads Consumer sector efforts to grow and maintain a portfolio of innovative external partnerships, collaborations and investments for the benefit of J&J's Consumer businesses, which currently reach across broad and diverse sectors such as oral care, compromised skin, baby and maternal health, personal care and beauty, an OTC platform anchored in pain relief, cough/cold, and digestive health, as well as digital health platforms. Previously, Stefanie was a Managing Director at Stonebridge Associates, a Boston-based investment banking firm that she helped found in 1996. She has over 20 years of experience in providing strategic and financial advisory services to small and midsized family-owned and growth companies in the consumer and healthcare sectors. Within that role she led mergers and acquisitions engagements, raised capital, defined business and financial strategy, performed complex due diligence and negotiated strategic alliances. In addition, Stefanie was independently consulting with several innovative startup and early-stage companies focused on the nutrition, health and wellness sector. Prior to Stonebridge, she worked at the Bank of New York. Stefanie has a Bachelor of Science degree in Finance and Operations & Strategic Management from Boston College
Connect with Stefanie:
Wesley Chen | Manager of External Innovation, Johnson and Johnson Innovation, Boston
Wesley is Manager of External Innovation at the Johnson & Johnson Innovation, Boston. In this role, he helps guide deals and collaborations across both pharmaceutical and consumer sectors. Within the pharmaceutical sector, he focuses on Cardiovascular and Metabolism, Neuroscience, and Infectious Diseases and Vaccines and provides support to the Consumer Sector by identifying innovative approaches to understanding the role of microbiome in oral and skin care. Previously, Wesley completed his graduate studies at MIT understanding the role of biological hydrogels as selective filters and identifying how mucosal barriers control bacterial virulence.
Kuldeep Neote, Ph.D. | Senior Director, New Ventures, Johnson & Johnson Innovation, Boston
Kuldeep is Senior Director of New Ventures at the Johnson & Johnson Innovation, Boston. He focuses primarily on the areas of Oncology and Immunology. A trained molecular biologist with an extensive background in drug discovery, Kuldeep has been focused on the areas of Immunology, Inflammation and Oncology and has a passion for implementing cutting edge scientific discoveries into practical drug discovery programs. Formerly, Kuldeep was Research Advisor/Director in Global External R&D at Eli Lilly. Prior to Eli Lilly, he was a Discovery Scientist at Pfizer, where he initiated the chemokine receptor drug discovery platform that led to the discovery and further development of several clinical candidates. Earlier in his career, Kuldeep also cloned one of the first chemokine receptors while at Genentech. Kuldeep earned his BSc. in Microbial and Cellular Biology at the University of Calgary, and a Ph.D. in Human and Molecule Genetics at the University of Toronto, where he was a major contributor in the understanding of the molecular basis of lysosomal storage diseases, in particular Tay Sachs and Sandhoff's disease.
Connect with Kuldeep:
Eric Schaeffer, Ph.D. | Senior Director, Neuroscience Scientific Innovation, Janssen R&D
Eric Schaeffer has more than 20 years of experience in the pharmaceutical industry, and has delivered multiple drug candidates to the clinic in both large and small company environments. Eric has an extensive background in the biology and pharmacology of CNS disorders including Alzheimer's disease, major depressive disorder, bipolar disorder and schizophrenia. In his current role at Janssen Eric is responsible for establishing and managing external partnerships in the areas of Mood Disorders and Alzheimer's disease. Previous roles held by Eric include Senior Director of Neuroscience Discovery at Pfizer where he was responsible for leading preclinical pharmacology, Director of Neuropharmacology at CHDI where he was responsible for initiating and managing biotech and academic partnerships focused on Huntington's disease and Director of Clinical Biomarkers at Bristol-Myers Squibb where he was responsible for developing the translational strategies for early clinical programs in the areas of schizophrenia, depression and neuromuscular diseases. Eric received his PhD from the Albert Einstein College of Medicine, and did postdoctoral work at MIT and Rockefeller University prior to initiating a career in the pharmaceutical industry.
About the Meet with... Series:
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, NCI, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCATS, NINDS, Johnson & Johnson Innovation, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.
About Johns Hopkins Technology Ventures
Johns Hopkins Technology Ventures (JHTV) is The Johns Hopkins University’s intellectual property administration center, serving Johns Hopkins researchers and inventors as a licensing, patent and technology commercialization office and acting as an active liaison to parties interested in leveraging university research or materials for academic or corporate endeavors. JHTV helps develop new discoveries and inventions into products and services that benefit society and transform the world. In 2014, JHTV secured more than $16 million in licensing revenue, more than 2,000 active issued patents and 13 newly created startup companies. For more information about Johns Hopkins Technology Ventures, opportunities to collaborate, start a technology venture or license a technology, visit http://ventures.jhu.edu/.